Who We are
We are innovative, collaborative and results-driven individuals, with a shared goal to improve the lives of patients and their families
Our Commitment To Patients
We believe that improving patient health begins with the science
U.S. FDA Accepts for Review Inebilizumab Biologics License Application for NMOSD
At Viela, we are working to redefine the treatment of autoimmune disease by focusing on pathways shared across various diseases. We believe this approach–which targets the underlying molecular pathogenesis of a disease– may enable us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple diseases with each product candidate. Our pipeline includes novel therapies for neuromyelitis optica spectrum disorder, kidney transplant rejection and Sjögren’s syndrome.